$PRNB Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Principia Biopharma Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Principia Biopharma Inc.. Get notifications about new insider transactions in Principia Biopharma Inc. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 05 2020 | PRNB | Principia Biopharm ... | Thomas Dolca | Chief Medical Offic ... | Option Exercise | A | 67.31 | 55,000 | 3,702,050 | 55,000 | |
| Mar 05 2020 | PRNB | Principia Biopharm ... | Hardiman Roy C. | Chief Business Offi ... | Option Exercise | A | 67.31 | 55,000 | 3,702,050 | 55,000 | |
| Mar 05 2020 | PRNB | Principia Biopharm ... | CHAI CHRISTOPHER Y | Chief Financial Off ... | Option Exercise | A | 67.31 | 55,000 | 3,702,050 | 55,000 | |
| Mar 05 2020 | PRNB | Principia Biopharm ... | Goldstein David | Chief Scientific Of ... | Option Exercise | A | 67.31 | 75,000 | 5,048,250 | 75,000 | |
| Mar 05 2020 | PRNB | Principia Biopharm ... | Babler Martin | President, CEO | Option Exercise | A | 67.31 | 200,000 | 13,462,000 | 200,000 | |
| Mar 05 2020 | PRNB | Principia Biopharm ... | Babler Martin | President, CEO | Sell | S | 64.83 | 300 | 19,448 | 39,179 | 39.5 K to 39.2 K (-0.76 %) |
| Mar 05 2020 | PRNB | Principia Biopharm ... | Babler Martin | President, CEO | Sell | S | 64.10 | 5,432 | 348,180 | 39,479 | 44.9 K to 39.5 K (-12.10 %) |
| Mar 05 2020 | PRNB | Principia Biopharm ... | Babler Martin | President, CEO | Sell | S | 63.24 | 7,183 | 454,251 | 44,911 | 52.1 K to 44.9 K (-13.79 %) |
| Mar 05 2020 | PRNB | Principia Biopharm ... | Babler Martin | President, CEO | Sell | S | 62.45 | 2,085 | 130,203 | 52,094 | 54.2 K to 52.1 K (-3.85 %) |
| Mar 05 2020 | PRNB | Principia Biopharm ... | Babler Martin | President, CEO | Gift | G | 0.00 | 1,159 | 0 | 18,355 | 17.2 K to 18.4 K (+6.74 %) |
| Mar 05 2020 | PRNB | Principia Biopharm ... | Babler Martin | President, CEO | Gift | G | 0.00 | 1,159 | 0 | 0 | 1.2 K to 0 (-100.00 %) |
| Feb 20 2020 | PRNB | Principia Biopharm ... | CHAI CHRISTOPHER Y | Chief Financial Off ... | Option Exercise | M | 3.00 | 2,500 | 7,494 | 70,157 | |
| Feb 20 2020 | PRNB | Principia Biopharm ... | CHAI CHRISTOPHER Y | Chief Financial Off ... | Sell | S | 68.52 | 76 | 5,208 | 4,766 | 4.8 K to 4.8 K (-1.57 %) |
| Feb 20 2020 | PRNB | Principia Biopharm ... | CHAI CHRISTOPHER Y | Chief Financial Off ... | Sell | S | 68.13 | 2,240 | 152,612 | 4,842 | 7.1 K to 4.8 K (-31.63 %) |
| Feb 20 2020 | PRNB | Principia Biopharm ... | CHAI CHRISTOPHER Y | Chief Financial Off ... | Sell | S | 67.08 | 605 | 40,582 | 7,082 | 7.7 K to 7.1 K (-7.87 %) |
| Feb 20 2020 | PRNB | Principia Biopharm ... | CHAI CHRISTOPHER Y | Chief Financial Off ... | Sell | S | 65.94 | 1,350 | 89,021 | 7,687 | 9 K to 7.7 K (-14.94 %) |
| Feb 20 2020 | PRNB | Principia Biopharm ... | CHAI CHRISTOPHER Y | Chief Financial Off ... | Sell | S | 64.91 | 545 | 35,375 | 9,037 | 9.6 K to 9 K (-5.69 %) |
| Feb 20 2020 | PRNB | Principia Biopharm ... | CHAI CHRISTOPHER Y | Chief Financial Off ... | Sell | S | 63.86 | 2,684 | 171,389 | 9,582 | 12.3 K to 9.6 K (-21.88 %) |
| Feb 20 2020 | PRNB | Principia Biopharm ... | CHAI CHRISTOPHER Y | Chief Financial Off ... | Buy | M | 3.00 | 2,500 | 7,494 | 12,266 | 9.8 K to 12.3 K (+25.60 %) |
| Feb 12 2020 | PRNB | Principia Biopharm ... | Goldstein David | Chief Scientific Of ... | Option Exercise | M | 3.00 | 6,000 | 17,986 | 8,447 | |
| Feb 12 2020 | PRNB | Principia Biopharm ... | Goldstein David | Chief Scientific Of ... | Sell | S | 71.11 | 5,200 | 369,779 | 30,968 | 36.2 K to 31 K (-14.38 %) |
| Feb 12 2020 | PRNB | Principia Biopharm ... | Goldstein David | Chief Scientific Of ... | Sell | S | 69.53 | 800 | 55,622 | 36,168 | 37 K to 36.2 K (-2.16 %) |
| Feb 12 2020 | PRNB | Principia Biopharm ... | Goldstein David | Chief Scientific Of ... | Buy | M | 3.00 | 6,000 | 17,986 | 36,968 | 31 K to 37 K (+19.37 %) |
| Dec 20 2019 | PRNB | Principia Biopharm ... | Thomas Dolca | Chief Medical Offic ... | Sell | S | 60.00 | 495 | 29,700 | 494 | 989 to 494 (-50.05 %) |
| Dec 20 2019 | PRNB | Principia Biopharm ... | Thomas Dolca | Chief Medical Offic ... | Sell | S | 60.00 | 495 | 29,700 | 494 | 989 to 494 (-50.05 %) |
| Dec 19 2019 | PRNB | Principia Biopharm ... | Babler Martin | President, CEO | Sell | S | 54.28 | 1,295 | 70,292 | 15,696 | 17 K to 15.7 K (-7.62 %) |
| Dec 19 2019 | PRNB | Principia Biopharm ... | Babler Martin | President, CEO | Sell | S | 53.69 | 2,205 | 118,392 | 16,991 | 19.2 K to 17 K (-11.49 %) |
| Dec 19 2019 | PRNB | Principia Biopharm ... | Babler Martin | President, CEO | Sell | S | 54.28 | 1,295 | 70,292 | 15,696 | 17 K to 15.7 K (-7.62 %) |
| Dec 19 2019 | PRNB | Principia Biopharm ... | Babler Martin | President, CEO | Sell | S | 52.77 | 1,000 | 52,775 | 19,196 | 20.2 K to 19.2 K (-4.95 %) |
| Dec 19 2019 | PRNB | Principia Biopharm ... | Babler Martin | President, CEO | Sell | S | 53.69 | 2,205 | 118,392 | 16,991 | 19.2 K to 17 K (-11.49 %) |
| Dec 19 2019 | PRNB | Principia Biopharm ... | Babler Martin | President, CEO | Sell | S | 54.36 | 1,014 | 55,116 | 54,179 | 55.2 K to 54.2 K (-1.84 %) |
| Dec 19 2019 | PRNB | Principia Biopharm ... | Babler Martin | President, CEO | Sell | S | 52.77 | 1,000 | 52,775 | 19,196 | 20.2 K to 19.2 K (-4.95 %) |
| Dec 19 2019 | PRNB | Principia Biopharm ... | Babler Martin | President, CEO | Sell | S | 53.94 | 6,661 | 359,314 | 55,193 | 61.9 K to 55.2 K (-10.77 %) |
| Dec 19 2019 | PRNB | Principia Biopharm ... | Babler Martin | President, CEO | Sell | S | 54.36 | 1,014 | 55,116 | 54,179 | 55.2 K to 54.2 K (-1.84 %) |
| Dec 19 2019 | PRNB | Principia Biopharm ... | Babler Martin | President, CEO | Sell | S | 52.86 | 11,485 | 607,064 | 61,854 | 73.3 K to 61.9 K (-15.66 %) |
| Dec 19 2019 | PRNB | Principia Biopharm ... | Babler Martin | President, CEO | Sell | S | 53.94 | 6,661 | 359,314 | 55,193 | 61.9 K to 55.2 K (-10.77 %) |
| Dec 19 2019 | PRNB | Principia Biopharm ... | Babler Martin | President, CEO | Sell | S | 51.80 | 5,840 | 302,502 | 73,339 | 79.2 K to 73.3 K (-7.38 %) |
| Dec 19 2019 | PRNB | Principia Biopharm ... | Babler Martin | President, CEO | Sell | S | 52.86 | 11,485 | 607,064 | 61,854 | 73.3 K to 61.9 K (-15.66 %) |
| Dec 19 2019 | PRNB | Principia Biopharm ... | Babler Martin | President, CEO | Sell | S | 51.80 | 5,840 | 302,502 | 73,339 | 79.2 K to 73.3 K (-7.38 %) |
| Dec 18 2019 | PRNB | Principia Biopharm ... | Wolff Stefani | Chief Development O ... | Option Exercise | M | 4.54 | 5,505 | 25,004 | 24,551 | |
| Dec 18 2019 | PRNB | Principia Biopharm ... | Wolff Stefani | Chief Development O ... | Sell | S | 49.87 | 1,300 | 64,825 | 35,609 | 36.9 K to 35.6 K (-3.52 %) |
| Dec 18 2019 | PRNB | Principia Biopharm ... | Wolff Stefani | Chief Development O ... | Sell | S | 49.29 | 4,205 | 207,266 | 36,909 | 41.1 K to 36.9 K (-10.23 %) |
| Dec 18 2019 | PRNB | Principia Biopharm ... | Wolff Stefani | Chief Development O ... | Buy | M | 4.54 | 5,505 | 25,004 | 41,114 | 35.6 K to 41.1 K (+15.46 %) |
| Dec 13 2019 | PRNB | Principia Biopharm ... | Hardiman Roy C. | Chief Business Offi ... | Option Exercise | M | 5.00 | 4,129 | 20,629 | 0 | |
| Dec 13 2019 | PRNB | Principia Biopharm ... | Hardiman Roy C. | Chief Business Offi ... | Option Exercise | M | 5.00 | 4,129 | 20,629 | 0 | |
| Dec 13 2019 | PRNB | Principia Biopharm ... | Hardiman Roy C. | Chief Business Offi ... | Option Exercise | M | 4.72 | 871 | 4,114 | 12,758 | |
| Dec 13 2019 | PRNB | Principia Biopharm ... | Hardiman Roy C. | Chief Business Offi ... | Option Exercise | M | 4.72 | 871 | 4,114 | 12,758 | |
| Dec 13 2019 | PRNB | Principia Biopharm ... | Hardiman Roy C. | Chief Business Offi ... | Sell | S | 49.83 | 1,619 | 80,682 | 120,143 | 121.8 K to 120.1 K (-1.33 %) |
| Dec 13 2019 | PRNB | Principia Biopharm ... | Hardiman Roy C. | Chief Business Offi ... | Sell | S | 49.83 | 1,619 | 80,682 | 120,143 | 121.8 K to 120.1 K (-1.33 %) |
| Dec 13 2019 | PRNB | Principia Biopharm ... | Hardiman Roy C. | Chief Business Offi ... | Sell | S | 49.20 | 3,381 | 166,352 | 121,762 | 125.1 K to 121.8 K (-2.70 %) |
| Dec 13 2019 | PRNB | Principia Biopharm ... | Hardiman Roy C. | Chief Business Offi ... | Sell | S | 49.20 | 3,381 | 166,352 | 121,762 | 125.1 K to 121.8 K (-2.70 %) |
| Dec 13 2019 | PRNB | Principia Biopharm ... | Hardiman Roy C. | Chief Business Offi ... | Buy | M | 5.00 | 4,129 | 20,629 | 125,143 | 121 K to 125.1 K (+3.41 %) |
| Dec 13 2019 | PRNB | Principia Biopharm ... | Hardiman Roy C. | Chief Business Offi ... | Buy | M | 5.00 | 4,129 | 20,629 | 125,143 | 121 K to 125.1 K (+3.41 %) |
| Dec 13 2019 | PRNB | Principia Biopharm ... | Hardiman Roy C. | Chief Business Offi ... | Buy | M | 4.72 | 871 | 4,114 | 121,014 | 120.1 K to 121 K (+0.72 %) |
| Dec 13 2019 | PRNB | Principia Biopharm ... | Hardiman Roy C. | Chief Business Offi ... | Buy | M | 4.72 | 871 | 4,114 | 121,014 | 120.1 K to 121 K (+0.72 %) |
| Nov 08 2019 | PRNB | Principia Biopharm ... | Goldstein David | Chief Scientific Of ... | Option Exercise | M | 3.00 | 1,075 | 3,223 | 14,447 | |
| Nov 08 2019 | PRNB | Principia Biopharm ... | Goldstein David | Chief Scientific Of ... | Option Exercise | M | 3.00 | 1,075 | 3,223 | 14,447 | |
| Nov 08 2019 | PRNB | Principia Biopharm ... | Goldstein David | Chief Scientific Of ... | Option Exercise | M | 1.91 | 1,651 | 3,149 | 0 | |
| Nov 08 2019 | PRNB | Principia Biopharm ... | Goldstein David | Chief Scientific Of ... | Option Exercise | M | 1.91 | 1,651 | 3,149 | 0 | |
| Nov 08 2019 | PRNB | Principia Biopharm ... | Goldstein David | Chief Scientific Of ... | Option Exercise | M | 1.91 | 6,147 | 11,726 | 0 | |
| Nov 08 2019 | PRNB | Principia Biopharm ... | Goldstein David | Chief Scientific Of ... | Option Exercise | M | 1.91 | 6,147 | 11,726 | 0 | |
| Nov 08 2019 | PRNB | Principia Biopharm ... | Goldstein David | Chief Scientific Of ... | Option Exercise | M | 0.64 | 1,127 | 717 | 0 | |
| Nov 08 2019 | PRNB | Principia Biopharm ... | Goldstein David | Chief Scientific Of ... | Option Exercise | M | 0.64 | 1,127 | 717 | 0 | |
| Nov 08 2019 | PRNB | Principia Biopharm ... | Goldstein David | Chief Scientific Of ... | Sell | S | 32.39 | 10,000 | 323,914 | 29,819 | 39.8 K to 29.8 K (-25.11 %) |
| Nov 08 2019 | PRNB | Principia Biopharm ... | Goldstein David | Chief Scientific Of ... | Sell | S | 32.39 | 10,000 | 323,914 | 29,819 | 39.8 K to 29.8 K (-25.11 %) |
| Nov 08 2019 | PRNB | Principia Biopharm ... | Goldstein David | Chief Scientific Of ... | Buy | M | 3.00 | 1,075 | 3,223 | 39,819 | 38.7 K to 39.8 K (+2.77 %) |
| Nov 08 2019 | PRNB | Principia Biopharm ... | Goldstein David | Chief Scientific Of ... | Buy | M | 3.00 | 1,075 | 3,223 | 39,819 | 38.7 K to 39.8 K (+2.77 %) |
| Nov 08 2019 | PRNB | Principia Biopharm ... | Goldstein David | Chief Scientific Of ... | Buy | M | 1.91 | 1,651 | 3,149 | 38,744 | 37.1 K to 38.7 K (+4.45 %) |
| Nov 08 2019 | PRNB | Principia Biopharm ... | Goldstein David | Chief Scientific Of ... | Buy | M | 1.91 | 1,651 | 3,149 | 38,744 | 37.1 K to 38.7 K (+4.45 %) |
| Nov 08 2019 | PRNB | Principia Biopharm ... | Goldstein David | Chief Scientific Of ... | Buy | M | 1.91 | 6,147 | 11,726 | 37,093 | 30.9 K to 37.1 K (+19.86 %) |
| Nov 08 2019 | PRNB | Principia Biopharm ... | Goldstein David | Chief Scientific Of ... | Buy | M | 1.91 | 6,147 | 11,726 | 37,093 | 30.9 K to 37.1 K (+19.86 %) |
| Nov 08 2019 | PRNB | Principia Biopharm ... | Goldstein David | Chief Scientific Of ... | Buy | M | 0.64 | 1,127 | 717 | 30,946 | 29.8 K to 30.9 K (+3.78 %) |
| Nov 08 2019 | PRNB | Principia Biopharm ... | Goldstein David | Chief Scientific Of ... | Buy | M | 0.64 | 1,127 | 717 | 30,946 | 29.8 K to 30.9 K (+3.78 %) |
| Oct 30 2019 | PRNB | Principia Biopharm ... | Becker Daniel J. | Director | Buy | P | 33.98 | 9,196 | 312,477 | 612,600 | 603.4 K to 612.6 K (+1.52 %) |
| Oct 30 2019 | PRNB | Principia Biopharm ... | Becker Daniel J. | Director | Buy | P | 33.41 | 68,404 | 2,285,549 | 603,404 | 535 K to 603.4 K (+12.79 %) |
| Oct 22 2019 | PRNB | Principia Biopharm ... | GLAXOSMITHKLINE PLC | Buy | P | 28.00 | 357,142 | 9,999,976 | 2,982,855 | 2.6 M to 3 M (+13.60 %) | |
| Oct 22 2019 | PRNB | Principia Biopharm ... | George Simeon | Director | Buy | P | 28.00 | 357,142 | 9,999,976 | 2,982,855 | 2.6 M to 3 M (+13.60 %) |
| Oct 22 2019 | PRNB | Principia Biopharm ... | Becker Daniel J. | Director | Buy | P | 28.00 | 535,000 | 14,980,000 | 535,000 | 0 to 535 K |
| Aug 30 2019 | PRNB | Principia Biopharm ... | Tomasello Shawn | Director | Option Exercise | A | 36.79 | 10,240 | 376,730 | 10,240 | |
| Aug 30 2019 | PRNB | Principia Biopharm ... | Tomasello Shawn | Director | Option Exercise | A | 36.79 | 20,475 | 753,275 | 20,475 | |
| Aug 30 2019 | PRNB | Principia Biopharm ... | Tomasello Shawn | Director | Option Exercise | A | 36.79 | 10,240 | 376,730 | 10,240 | |
| Aug 30 2019 | PRNB | Principia Biopharm ... | Tomasello Shawn | Director | Option Exercise | A | 36.79 | 20,475 | 753,275 | 20,475 | |
| Aug 15 2019 | PRNB | Principia Biopharm ... | New Leaf Ventures II, L.P. | 10% Owner | Sell | S | 35.00 | 49,991 | 1,749,685 | 387,546 | 437.5 K to 387.5 K (-11.43 %) |
| Aug 15 2019 | PRNB | Principia Biopharm ... | New Leaf Ventures II, L.P. | 10% Owner | Sell | S | 35.00 | 250,009 | 8,750,315 | 1,938,167 | 2.2 M to 1.9 M (-11.43 %) |
| Jun 17 2019 | PRNB | Principia Biopharm ... | GLAXOSMITHKLINE PLC | 10% Owner | Option Exercise | A | 31.77 | 10,240 | 325,325 | 10,240 | |
| Jun 11 2019 | PRNB | Principia Biopharm ... | Machado Patrick | Director | Option Exercise | A | 31.77 | 10,240 | 325,325 | 10,240 | |
| Jun 11 2019 | PRNB | Principia Biopharm ... | Machado Patrick | Director | Option Exercise | A | 31.77 | 20,475 | 650,491 | 20,475 | |
| Jun 11 2019 | PRNB | Principia Biopharm ... | Lin Shao-Lee | Director | Option Exercise | A | 31.77 | 10,240 | 325,325 | 10,240 | |
| Jun 11 2019 | PRNB | Principia Biopharm ... | George Simeon | Director | Option Exercise | A | 31.77 | 10,240 | 325,325 | 10,240 | |
| Jun 11 2019 | PRNB | Principia Biopharm ... | Becker Daniel J. | Director | Option Exercise | A | 31.77 | 10,240 | 325,325 | 10,240 | |
| Jun 11 2019 | PRNB | Principia Biopharm ... | Colowick Alan | Director | Option Exercise | A | 31.77 | 10,240 | 325,325 | 10,240 | |
| May 22 2019 | PRNB | Principia Biopharm ... | ORBIMED ADVISORS LLC | 10% Owner | Sell | S | 30.25 | 1,000,000 | 30,250,000 | 1,605,713 | 2.6 M to 1.6 M (-38.38 %) |
| Apr 18 2019 | PRNB | Principia Biopharm ... | Lin Shao-Lee | Director | Option Exercise | A | 27.81 | 20,475 | 569,410 | 20,475 | |
| Mar 08 2019 | PRNB | Principia Biopharm ... | Wolff Stefani | Chief Development O ... | Option Exercise | A | 35.42 | 60,000 | 2,125,200 | 60,000 | |
| Mar 08 2019 | PRNB | Principia Biopharm ... | Thomas Dolca | Chief Medical Offic ... | Option Exercise | A | 35.42 | 60,000 | 2,125,200 | 60,000 | |
| Mar 08 2019 | PRNB | Principia Biopharm ... | Goldstein David | Chief Scientific Of ... | Option Exercise | A | 35.42 | 60,000 | 2,125,200 | 60,000 | |
| Mar 08 2019 | PRNB | Principia Biopharm ... | Hardiman Roy C. | Chief Business Offi ... | Option Exercise | A | 35.42 | 60,000 | 2,125,200 | 60,000 | |
| Mar 08 2019 | PRNB | Principia Biopharm ... | CHAI CHRISTOPHER Y | Chief Financial Off ... | Option Exercise | A | 35.42 | 60,000 | 2,125,200 | 60,000 | |
| Mar 08 2019 | PRNB | Principia Biopharm ... | Babler Martin | Chief Executive Off ... | Option Exercise | A | 35.42 | 155,000 | 5,490,100 | 155,000 | |
| Feb 21 2019 | PRNB | Principia Biopharm ... | Smither John W | Director | Option Exercise | A | 30.30 | 20,475 | 620,393 | 20,475 | |
| Jan 15 2019 | PRNB | Principia Biopharm ... | GLAXOSMITHKLINE PLC | 10% Owner | Option Exercise | A | 17.00 | 20,475 | 348,075 | 20,475 | |
| Jan 10 2019 | PRNB | Principia Biopharm ... | Shuster Lewis | Director | Option Exercise | A | 17.00 | 20,475 | 348,075 | 20,475 | |
| Jan 10 2019 | PRNB | Principia Biopharm ... | George Simeon | Director | Option Exercise | A | 17.00 | 20,475 | 348,075 | 20,475 | |
| Jan 10 2019 | PRNB | Principia Biopharm ... | Colowick Alan | Director | Option Exercise | A | 17.00 | 20,475 | 348,075 | 20,475 | |
| Jan 10 2019 | PRNB | Principia Biopharm ... | Becker Daniel J. | Director | Option Exercise | A | 17.00 | 20,475 | 348,075 | 20,475 | |
| Jan 10 2019 | PRNB | Principia Biopharm ... | AKKARAJU SRINIVAS | Director | Option Exercise | A | 17.00 | 20,475 | 348,075 | 20,475 | |
| Sep 20 2018 | PRNB | Principia Biopharm ... | Sofinnova Venture Partners VII ... | 10% Owner | Option Exercise | C | 0.00 | 167,537 | 0 | 0 | |
| Sep 20 2018 | PRNB | Principia Biopharm ... | Sofinnova Venture Partners VII ... | 10% Owner | Option Exercise | C | 0.00 | 453,954 | 0 | 0 | |
| Sep 20 2018 | PRNB | Principia Biopharm ... | Sofinnova Venture Partners VII ... | 10% Owner | Option Exercise | C | 0.00 | 521,235 | 0 | 0 | |
| Sep 20 2018 | PRNB | Principia Biopharm ... | Sofinnova Venture Partners VII ... | 10% Owner | Option Exercise | C | 0.00 | 625,482 | 0 | 0 | |
| Sep 20 2018 | PRNB | Principia Biopharm ... | Sofinnova Venture Partners VII ... | 10% Owner | Buy | P | 17.00 | 270,000 | 4,590,000 | 2,038,208 | 1.8 M to 2 M (+15.27 %) |
| Sep 20 2018 | PRNB | Principia Biopharm ... | Sofinnova Venture Partners VII ... | 10% Owner | Buy | C | 0.00 | 167,537 | 0 | 1,768,208 | 1.6 M to 1.8 M (+10.47 %) |
| Sep 20 2018 | PRNB | Principia Biopharm ... | Sofinnova Venture Partners VII ... | 10% Owner | Buy | C | 0.00 | 453,954 | 0 | 1,600,671 | 1.1 M to 1.6 M (+39.59 %) |
| Sep 20 2018 | PRNB | Principia Biopharm ... | Sofinnova Venture Partners VII ... | 10% Owner | Buy | C | 0.00 | 521,235 | 0 | 1,146,717 | 625.5 K to 1.1 M (+83.33 %) |
| Sep 20 2018 | PRNB | Principia Biopharm ... | Sofinnova Venture Partners VII ... | 10% Owner | Buy | C | 0.00 | 625,482 | 0 | 625,482 | 0 to 625.5 K |
| Sep 20 2018 | PRNB | Principia Biopharm ... | ORBIMED ADVISORS LLC | 10% Owner | Option Exercise | C | 0.00 | 167,537 | 0 | 0 | |
| Sep 20 2018 | PRNB | Principia Biopharm ... | ORBIMED ADVISORS LLC | 10% Owner | Option Exercise | C | 0.00 | 544,047 | 0 | 0 | |
| Sep 20 2018 | PRNB | Principia Biopharm ... | ORBIMED ADVISORS LLC | 10% Owner | Option Exercise | C | 0.00 | 260,617 | 0 | 0 | |
| Sep 20 2018 | PRNB | Principia Biopharm ... | ORBIMED ADVISORS LLC | 10% Owner | Option Exercise | C | 0.00 | 312,741 | 0 | 0 | |
| Sep 20 2018 | PRNB | Principia Biopharm ... | ORBIMED ADVISORS LLC | 10% Owner | Option Exercise | C | 0.00 | 1,070,771 | 0 | 0 | |
| Sep 20 2018 | PRNB | Principia Biopharm ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | P | 17.00 | 250,000 | 4,250,000 | 2,605,713 | 2.4 M to 2.6 M (+10.61 %) |
| Sep 20 2018 | PRNB | Principia Biopharm ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | C | 0.00 | 167,537 | 0 | 2,355,713 | 2.2 M to 2.4 M (+7.66 %) |
| Sep 20 2018 | PRNB | Principia Biopharm ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | C | 0.00 | 544,047 | 0 | 2,188,176 | 1.6 M to 2.2 M (+33.09 %) |
| Sep 20 2018 | PRNB | Principia Biopharm ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | C | 0.00 | 260,617 | 0 | 1,644,129 | 1.4 M to 1.6 M (+18.84 %) |
| Sep 20 2018 | PRNB | Principia Biopharm ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | C | 0.00 | 312,741 | 0 | 1,383,512 | 1.1 M to 1.4 M (+29.21 %) |
| Sep 20 2018 | PRNB | Principia Biopharm ... | ORBIMED ADVISORS LLC | 10% Owner | Buy | C | 0.00 | 1,070,771 | 0 | 1,070,771 | 0 to 1.1 M |
| Sep 20 2018 | PRNB | Principia Biopharm ... | Becker Daniel J. | Director | Option Exercise | C | 0.00 | 167,537 | 0 | 0 | |
| Sep 20 2018 | PRNB | Principia Biopharm ... | Becker Daniel J. | Director | Option Exercise | C | 0.00 | 544,047 | 0 | 0 | |
| Sep 20 2018 | PRNB | Principia Biopharm ... | Becker Daniel J. | Director | Option Exercise | C | 0.00 | 260,617 | 0 | 0 | |
| Sep 20 2018 | PRNB | Principia Biopharm ... | Becker Daniel J. | Director | Option Exercise | C | 0.00 | 312,741 | 0 | 0 | |
| Sep 20 2018 | PRNB | Principia Biopharm ... | Becker Daniel J. | Director | Option Exercise | C | 0.00 | 1,070,771 | 0 | 0 | |
| Sep 20 2018 | PRNB | Principia Biopharm ... | Becker Daniel J. | Director | Buy | P | 17.00 | 270,000 | 4,590,000 | 437,537 | 167.5 K to 437.5 K (+161.16 %) |
| Sep 20 2018 | PRNB | Principia Biopharm ... | Becker Daniel J. | Director | Buy | C | 0.00 | 167,537 | 0 | 167,537 | 0 to 167.5 K |
| Sep 20 2018 | PRNB | Principia Biopharm ... | Becker Daniel J. | Director | Buy | C | 0.00 | 544,047 | 0 | 2,188,176 | 1.6 M to 2.2 M (+33.09 %) |
| Sep 20 2018 | PRNB | Principia Biopharm ... | Becker Daniel J. | Director | Buy | C | 0.00 | 260,617 | 0 | 1,644,129 | 1.4 M to 1.6 M (+18.84 %) |
| Sep 20 2018 | PRNB | Principia Biopharm ... | Becker Daniel J. | Director | Buy | C | 0.00 | 312,741 | 0 | 1,383,512 | 1.1 M to 1.4 M (+29.21 %) |
| Sep 20 2018 | PRNB | Principia Biopharm ... | Becker Daniel J. | Director | Buy | C | 0.00 | 1,070,771 | 0 | 1,070,771 | 0 to 1.1 M |
| Sep 20 2018 | PRNB | Principia Biopharm ... | New Leaf Ventures II, L.P. | 10% Owner | Option Exercise | C | 0.00 | 167,537 | 0 | 0 | |
| Sep 20 2018 | PRNB | Principia Biopharm ... | New Leaf Ventures II, L.P. | 10% Owner | Option Exercise | C | 0.00 | 544,047 | 0 | 0 | |
| Sep 20 2018 | PRNB | Principia Biopharm ... | New Leaf Ventures II, L.P. | 10% Owner | Option Exercise | C | 0.00 | 260,617 | 0 | 0 | |
| Sep 20 2018 | PRNB | Principia Biopharm ... | New Leaf Ventures II, L.P. | 10% Owner | Option Exercise | C | 0.00 | 312,741 | 0 | 0 | |
| Sep 20 2018 | PRNB | Principia Biopharm ... | New Leaf Ventures II, L.P. | 10% Owner | Option Exercise | C | 0.00 | 1,070,771 | 0 | 0 | |
| Sep 20 2018 | PRNB | Principia Biopharm ... | New Leaf Ventures II, L.P. | 10% Owner | Buy | P | 17.00 | 270,000 | 4,590,000 | 437,537 | 167.5 K to 437.5 K (+161.16 %) |
| Sep 20 2018 | PRNB | Principia Biopharm ... | New Leaf Ventures II, L.P. | 10% Owner | Buy | C | 0.00 | 167,537 | 0 | 167,537 | 0 to 167.5 K |
| Sep 20 2018 | PRNB | Principia Biopharm ... | New Leaf Ventures II, L.P. | 10% Owner | Buy | C | 0.00 | 544,047 | 0 | 2,188,176 | 1.6 M to 2.2 M (+33.09 %) |
| Sep 20 2018 | PRNB | Principia Biopharm ... | New Leaf Ventures II, L.P. | 10% Owner | Buy | C | 0.00 | 260,617 | 0 | 1,644,129 | 1.4 M to 1.6 M (+18.84 %) |
| Sep 20 2018 | PRNB | Principia Biopharm ... | New Leaf Ventures II, L.P. | 10% Owner | Buy | C | 0.00 | 312,741 | 0 | 1,383,512 | 1.1 M to 1.4 M (+29.21 %) |
| Sep 20 2018 | PRNB | Principia Biopharm ... | New Leaf Ventures II, L.P. | 10% Owner | Buy | C | 0.00 | 1,070,771 | 0 | 1,070,771 | 0 to 1.1 M |
| Sep 20 2018 | PRNB | Principia Biopharm ... | George Simeon | Director | Option Exercise | C | 0.00 | 167,537 | 0 | 0 | |
| Sep 20 2018 | PRNB | Principia Biopharm ... | George Simeon | Director | Option Exercise | C | 0.00 | 544,047 | 0 | 0 |